The White House has formally withdrawn Heidi Overton's nomination to serve as commissioner of the Food and Drug Administration, according to a confirmation provided to The Hill. The move comes just days before a scheduled committee vote that was expected to fail due to opposition from Senate Republicans.

Overton, currently deputy director of the White House Domestic Policy Council, was set to appear before the Senate Health, Education, Labor, and Pensions Committee on Wednesday. Republicans hold a slim one-vote majority on the panel, meaning a single defection would have doomed her nomination if all Democrats voted against it. GOP leaders could have bypassed the committee and brought her straight to the floor, but that path was seen as fraught with procedural hurdles and likely resistance.

Read also
Healthcare
Bipartisan ASAP Act aims to expand Medicare coverage for Alzheimer's blood tests
Lawmakers from both parties are backing the ASAP Act to require Medicare to cover FDA-approved blood tests for Alzheimer's and other dementias, citing personal stories and long-term savings.

Overton had been a controversial pick from the start. She was tapped to replace Marty Makary, who resigned in May, and immediately faced scrutiny from both some Republicans and influential figures in the Make America Healthy Again (MAHA) movement, which is closely aligned with Health Secretary Robert F. Kennedy Jr.

Senate health committee chairman Bill Cassidy (R-La.) had voiced concerns about Overton's role in the administration's vaccine policy changes. Last summer, Overton stood beside President Trump when he signed an executive order aimed at separating and reducing the childhood vaccine schedule, which she called "historic." Cassidy publicly criticized that action.

During her September confirmation hearing, Overton declined to say whether Trump was wrong on vaccines and would not commit to challenging the president or Kennedy. She also faced pointed questions from Sen. Lisa Murkowski (R-Alaska) about abortion, particularly regarding the abortion pill mifepristone. Overton, who is openly anti-abortion, had previously called the Supreme Court's 2022 ruling overturning Roe v. Wade "a huge victory for life," but she refused to state directly whether she believed mifepristone was safe.

Additional allegations emerged from Calley Means, a former senior adviser to Kennedy and a prominent MAHA voice, who claimed Overton had authored a policy that eased restrictions on fruit-flavored vapes. Means also alleged she helped the Justice Department construct a legal argument for the Supreme Court to take up a case that would shield chemical giant Bayer from lawsuits related to its pesticide products.

The FDA has been in turmoil, with a wave of senior staff departures and growing perceptions within the healthcare industry that the agency has become more politicized and less reliable than under previous administrations. Industry analysts said Overton's withdrawal would likely prolong that instability, though it remains unclear who the administration will nominate next.

The White House has not announced a replacement. The withdrawal marks a significant setback for the administration's health agenda, which has prioritized vaccine skepticism and deregulation under Kennedy's leadership.